[Prevention of peri-operative infection with levofloxacin in female patients undergoing surgery for stress urinary incontinence].
OBJECTIVE
To investigate the effect and safety of sequential therapy of levofloxacin in prevention of peri-operative infection among female patients undergoing surgery for stress urinary incontinence (SUI).


METHODS
85 female SUI patients, aged 58, with the average body weight of 63 g, underwent transvaginal tape (TVT) procedure. Levofloxacin 500 mg was given to 24 of the 85 patients who underwent simultaneous hysterectomy by intravenous injection since 1 day after the operation once a day and then given orally once a day for 4-8 days when the condition was improved. And levofloxacin 500 mg was given by intravenous injection to 61 of the 85 patients who were to underwent simple TVT 30 min before the operation and then was given orally 500 mg once a day for 4 days. The clinical efficacy and side reaction were observed.


RESULTS
The average duration of intravenous injection of levofloxacin in the patients who underwent hysterectomy was 2.5 d, and the duration of oral administration of levofloxacin was 5.7 d. The duration of oral administration of levofloxacin in the patients who underwent simple TVT was 3.2 d. No infection was seen in 85 patients with an efficient rate of 95.3%. No infection was found in all the 61 patients who underwent simple TVT with an efficient prevention rate of 100%. The overall side reaction rate was 5.9%. Only 3 patients showed mild gastroenterological reaction and 2 patients showed rashes.


CONCLUSIONS
Sequential therapy of levofloxacin is effective and safe in prevention of peri-operative infection in female patients undergoing surgery for stress urinary incontinence.
Cao
Dong-yan
DY
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhu
Lan
L
Wang
Jin-hui
JH
Zhang
Yu
Y
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000379:methods*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D064704:Levofloxacin; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013607:Tablets; D016896:Treatment Outcome; D014550:Urinary Incontinence, Stress / Q000601:surgery*; D014552:Urinary Tract Infections / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D013607:Tablets; D064704:Levofloxacin; D015242:Ofloxacin